文献速递肿瘤 PET/CT

68Ga-DOTA-FAPI-04 PET/CT肿瘤显像:与18F-FDG PET/CT在22种不同癌症类型中的比较

Tumor Imaging With 68Ga-DOTA-FAPI-04 PET/CT: Comparison With 18F-FDG PET/CT in 22 Different Cancer Types.
PubMed 文献 · Clin Nucl Med · 2022-01-01

纳入42例(女16例、男26例;平均年龄58.5岁,范围31-84岁)22种恶性疾病患者,在18F-FDG PET/CT后1至7天行68Ga-DOTA-FAPI-04 PET/CT,比较原发灶、淋巴结、骨骼、肝脏、腹膜等部位摄取;68Ga-DOTA-FAPI-04 PET/CT在原发肿瘤病灶中94.2%呈浓聚,多发性骨髓瘤中18F-FDG骨髓摄取显著高于68Ga-FAPI,胃印戒细胞肿瘤中68Ga-FAPI摄取显著高于18F-FDG,且骨、肝、腹膜转移检出敏感性和准确性更高。

要点

  • 68Ga-DOTA-FAPI-04 PET/CT在原发肿瘤病灶中94.2%呈浓聚。
  • 多发性骨髓瘤中18F-FDG骨髓摄取显著高于68Ga-FAPI摄取。
  • 胃印戒细胞肿瘤中68Ga-FAPI摄取显著高于18F-FDG摄取。

核心结论

  • 本研究的初步发现显示,68Ga-DOTA-FAPI-04 PET/CT可对实体瘤的诊断过程有所贡献。
  • 尤其在18F-FDG PET/CT摄取轻微的恶性肿瘤中,68Ga-DOTA-FAPI-04 PET/CT在诊断、分期和再分期方面表现突出。
  • 作者预测,FAPI分子可用于对其他治疗无反应且68Ga-DOTA-FAPI-04 PET/CT显示浓聚的转移性疾病患者进行放射性核素治疗。

研究设计与样本

  • 研究纳入42例(女16例、男26例;平均年龄58.5岁,范围31-84岁)22种不同类型恶性疾病患者。
  • 在18F-FDG PET/CT后1至7天行68Ga-DOTA-FAPI-04 PET/CT显像。
  • 比较两种PET/CT在原发肿瘤病灶、淋巴结、骨骼系统、肝脏、腹膜表面及其他身体部位的病理性摄取水平。
  • 通过测量肝脏、胸主动脉、臀肌活性及女性患者子宫活性,定义18F-FDG与68Ga-FAPI的生理性摄取水平。
  • 42例中33例用于分期、8例用于再分期、1例用于疗效评估。

主要发现

  • 68Ga-DOTA-FAPI-04 PET/CT在原发肿瘤病灶中94.2%显示浓聚。
  • 多发性骨髓瘤患者中,18F-FDG骨髓摄取显著高于68Ga-FAPI摄取。
  • 胃印戒细胞肿瘤患者中,68Ga-FAPI摄取显著高于18F-FDG摄取。
  • 68Ga-DOTA-FAPI-04 PET/CT检出骨、肝、腹膜转移的敏感性和准确性高于18F-FDG PET/CT。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文结论称本研究的发现为初步发现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION AND AIM: Cancer-associated fibroblasts, which are densely found in tumor tissue, express high levels of fibroblast activation protein (FAP), and FAP inhibitors (FAPIs) labeled with radionuclides can be used in the diagnosis and treatment of cancer. In this study, the role of 68Ga-DOTA-FAPI-04 PET/CT in imaging of primary, metastatic, and recurrent cancers was investigated. PATIENTS AND METHODS: A total of 42 patients (16 females, 26 males; mean age, 58.5 years; range, 31-84 years) with 22 different types of malignant diseases were included in the study. 68Ga-DOTA-FAPI-04 PET/CT imaging was performed 1 to 7 days after 18F-FDG PET/CT. Pathological uptake levels in primary tumoral lesions, lymph nodes, skeletal system, liver, peritoneal surfaces, and other body parts were compared between 2 PET/CTs. In addition, physiological uptake levels of 18F-FDG and 68Ga-FAPI were defined measuring the liver, thoracic aorta, gluteal muscle activities, and uterus activity in female patients. RESULTS: Of the 42 patients in the study group, 33 patients were included for staging, 8 patients for restaging, and 1 patient for evaluation of treatment response. 68Ga-DOTA-FAPI-04 PET/CT showed intense uptake in 94.2% of primary tumoral lesions. In patients with multiple myeloma, 18F-FDG uptake in the bone marrow was significantly higher than 68Ga-FAPI uptake, whereas in gastric signet ring cell tumors, 68Ga-FAPI uptake was found to be significantly higher than 18F-FDG uptake. It was observed that 68Ga-DOTA-FAPI-04 PET/CT detected bone, liver, and peritoneum metastases with higher sensitivity and accuracy compared 18F-FDG PET/CT. CONCLUSIONS: The preliminary findings of this study showed that 68Ga-DOTA-FAPI-04 PET/CT can contribute to the diagnostic process in solid tumors. Especially in malignancies with mild uptake on 18F-FDG PET/CT, it stands out in diagnosis, staging, and restaging. It is also predicted that FAPI molecules can be used for radionuclide therapy in patients with metastatic disease and unresponsive to other treatments showing intense uptake on 68Ga-DOTA-FAPI-04 PET/CT.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Çermik TF, Ergül N, Yılmaz B, et al. Tumor Imaging With 68Ga-DOTA-FAPI-04 PET/CT: Comparison With 18F-FDG PET/CT in 22 Different Cancer Types. Clin Nucl Med. 2022. PMID: 35085165. doi:10.1097/RLU.0000000000004073

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。